Novartis’ exit from mass-market generics highlights a structural shift as MNCs chase innovation while Indian drugmakers scale branded generics.
Novartis exit signals a strategic turning point
Novartis’ decision to exit India’s mass-market generics business marks a decisive shift in the country’s pharmaceutical landscape.
Last month, the Swiss drugmaker agreed to sell its 70.68% stake in Novartis India Ltd (NIL) to a private-equity consortium led by WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners. If the open offer succeeds, the deal could reach ₹2,000 crore, ending Novartis’ long presence in India’s public markets.
For decades, multinational pharma companies and Indian drugmakers operated in complementary roles. MNCs brought innovation and patented medicines, while domestic firms built scale through generics manufacturing and cost efficiency.
That overlap—once the industry’s backbone—is now fading.
The rise of the “innovation-first” playbook
Novartis has spent years repositioning itself as a pure-play innovative medicines company.
Amitabh Dube, country president and managing director of Novartis India, says the company now prioritizes therapies addressing high unmet medical needs.
Key focus areas include:
- Cardio-renal metabolic diseases
- Oncology treatments
- First-in-class or best-in-class therapies
As disease patterns shift toward chronic and non-communicable illnesses, patented drugs promise higher value than mass-market generics.
India still plays a critical role—but increasingly as an innovation hub rather than a sales market.
- The Novartis Corporate Centre in Hyderabad employs 9,000+ scientists, its largest global capability center.
- Nearly every molecule launched globally receives support from Indian teams.
In short: innovation stays in India, legacy brands don’t.
Pfizer mirrors the shift
Novartis is not alone.
Pfizer is also repositioning India as a strategic innovation hub, according to country president Meenakshi Nevatia.
Several signals highlight the shift:
- 70% of Pfizer medicines sold in India are locally manufactured.
- The company operates its largest sterile injectable facility outside the US in the country.
- Its Chennai R&D centre employs over 2,000 researchers.
- Around 40 global clinical trials are now conducted in India.
At the same time, Pfizer increasingly licenses marketing rights to Indian companies.
A recent example: Cipla’s partnership to distribute five Pfizer brands, including Corex and Dolonex, while Pfizer retains manufacturing and intellectual property.
Think of it like a tech company licensing software while letting local firms handle distribution.
Why MNCs are stepping away from generics
Analysts say the shift reflects structural economics, not financial distress.
Krishnanath Munde of India Ratings and Research notes several pressures:
- Drug price caps
- Patent disputes
- Operational complexity in branded generics markets
Instead of competing in price-controlled segments, MNCs now focus on specialty therapies with stronger margins.
Vivek Tandon of Primus Partners says the move is about strategic alignment.
Legacy brands still generate cash. But they often:
- Dilute margins
- Increase operational complexity
- Distract from innovation investments
For research-driven pharma giants, that trade-off increasingly looks unnecessary.
Indian pharma moves up the value chain
As MNCs divest legacy brands, Indian companies are eagerly buying them.
Why?
These medicines often have strong doctor recall, steady demand, and reliable cash flow.
Recent deals illustrate the trend:
- Cipla markets Novartis’ diabetes drug Galvus
- Dr Reddy’s sells Voveran
- Emcure acquired Sanofi cardiac brands
- Sanofi divested Soframycin to Encube
More deals are expected.
The market impact is already visible.
According to Pharmarack data, MNC share of India’s pharma market fell from 22% in 2013 to 14% in 2025.
Yet paradoxically, MNC revenues often grow faster, driven by high-value patented drugs.
Motilal Oswal and IQVIA data show MNC pharma growth at 10.7% in January 2025, compared with 8.3% for Indian companies.
Higher value per molecule beats sheer volume.
The widening strategic divide
The divergence ultimately reflects two very different business models.
Multinational pharma companies focus on:
- Innovation and intellectual property
- High-value specialty therapies
- Global scale
Indian drugmakers prioritize:
- Generics and branded generics
- Domestic market expansion
- Commercial reach and affordability
One anonymous Mumbai-based pharma CEO summed it up bluntly:
“The domestic market is bread-and-butter for Indian players. For MNCs, it’s only a small fraction of global revenue.”
The bigger question: Can India keep up in innovation?
The real challenge may lie ahead.
Indian pharma companies currently invest 6–7% of revenue in R&D, far below the 15–20% typical of global pharma majors.
As disease burdens shift toward complex chronic illnesses, innovation will matter more than ever.
Can India’s generics champions evolve into innovation leaders—or will the gap widen further?
That answer will shape the next chapter of the country’s $50-billion pharmaceutical industry.
TL;DR:
Novartis’ exit from India’s mass-market generics business highlights a structural split in pharma. MNCs are focusing on innovation and patented drugs, while Indian companies scale branded generics by acquiring legacy brands. The shift benefits both sides but raises questions about India’s long-term R&D capabilities.
AI summary
- Novartis sells 70.68% stake in Novartis India Ltd, exiting generics.
- MNCs pivot to innovation, patents, and specialty therapies.
- India becomes R&D and clinical trials hub for global pharma.
- Domestic firms acquire legacy brands for scale and cash flow.
- India’s R&D spending gap could shape future competitiveness.
